1-2 of 2
Helen Bishop
Close
Sort by
Journal Articles

Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

Kirsten Fischer, MD, Anna-Maria Fink, MD, Helen Bishop, Mark Dixon, Jasmin Bahlo, Michael Y. Choi, MD, Robert Weinkove, MD PhD, K. Sue Robinson, MD, Martin Dreyling, MD PhD, Till Seiler, MD, Stephen Opat, MD, Carolyn Owen, MD, Javier Lopez, Sr., MD PhD, Nadine Kutsch, MD, Eugen Tausch, MD, Matthias Ritgen, MD, Rod A. Humerickhouse, MD PhD, Kathryn Humphrey, Michael K. Wenger, MD, Valentin Goede, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Thomas J. Kipps, MD PhD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 496.
https://doi.org/10.1182/blood.V126.23.496.496
Published: 2015
Journal Articles

Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial

Valentin Goede, Kirsten Fischer, Busch Raymonde, Jaeger Ulrich, Marie-Sarah Dilhuydy, Nicholas Wickham, Sophie De Guibert, Anna Maria Fink, Susanne Hagist, Natali Pflug, Jasmin Bahlo, Gabriele Kranz, Gabriel Bieska, Kathryn Humphrey, Helen Bishop, Michael Wenger, Michael Hallek
Journal: Blood
Blood (2010) 116 (21): 1387.
https://doi.org/10.1182/blood.V116.21.1387.1387
Published: 2010